Arch Biopartners to Raise CA$900,000 Via Non-Brokered Private Placement

11:22 AM EST, 11/06/2026 (MT Newswires) -- Arch Biopartners (ARCH.V) plans to raise gross proceeds of CA$900,000 through a non-brokered private placement offering, it said Friday. The private placement will include around 1.06-million common shares priced at CA$0.85 each, the company said. The company expects the offering, which is subject to certain conditions, to settle on or about Nov. 12, it said. The company will use the proceeds to begin onboarding clinical sites in the US for its Phase II trial for LSALT peptide targeting cardiac surgery-associated acute kidney injury, to "accelerate" pre-clinical studies for the company's IL-32 chronic kidney disease program, to "market" the company to a "larger financial and industry audience", and for general working capital to be used for operating expenses, it added. The company's shares were last seen up CA$0.04 or 4.8%, at CA$0.87, on the TSX Venture Exchange. Price: 0.87, Change: +0.04, Percent Change: +4.82